Floatz logo

Abiraterone Acetate

Neoadjuvant

Seoul National University HospitalDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Neoadjuvant cohort.

Asset / SponsorPhaseRating
Toripalimab
ZHOU FANGJIAN
Phase 3B
Axitinib
ZHOU FANGJIAN
Phase 3B
Carboplatin
AbbVie
Phase 2CCC
Irinotecan
AbbVie
Phase 2CCC
(+)-VINCRISTINE
AbbVie
Phase 2CCC

View all 11 →

Same molecule, other indications

Abiraterone Acetate is also rated in:

prostate carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Metastatic Castration Resistant Prostate CancerDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →